KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $131.4 million.

  • Recursion Pharmaceuticals' Net Cash Flow rose 37772.0% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.8 million, marking a year-over-year increase of 46936.31%. This contributed to the annual value of $205.0 million for FY2024, which is 22985.27% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Net Cash Flow of $131.4 million as of Q3 2025, which was up 37772.0% from $15.4 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Net Cash Flow registered a high of $423.8 million during Q2 2021, and its lowest value of -$238.0 million during Q3 2021.
  • Over the past 5 years, Recursion Pharmaceuticals' median Net Cash Flow value was -$19.5 million (recorded in 2023), while the average stood at $20.4 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Net Cash Flow crashed by 260025.64% in 2023, and later soared by 406866.15% in 2024.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Net Cash Flow stood at -$109.6 million in 2021, then surged by 186.25% to $94.5 million in 2022, then plummeted by 95.67% to $4.1 million in 2023, then surged by 4068.66% to $170.7 million in 2024, then dropped by 22.99% to $131.4 million in 2025.
  • Its Net Cash Flow was $131.4 million in Q3 2025, compared to $15.4 million in Q2 2025 and -$98.7 million in Q1 2025.